Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: Outcomes from TECOS. by Engel, S, Suryawanshi, S, Stevens, S, Josse, R, Cornel, J, Jakuboniene, N, Riefflin, A, Tankova, T, Wainstein, J, Peterson, E, Holman, R, TECOS Study Group

Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS. by Cornel, J, Bakris, G, Stevens, S, Alvarsson, M, Bax, W, Chuang, L, Engel, S, Lopes, R, McGuire, D, Riefflin, A, Rodbard, H, Sinay, I, Tankova, T, Wainstein, J, Peterson, E, Holman, R

Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial by McGuire, D, Van De Werf, F, Armstrong, P, Standl, E, Koglin, J, Green, J, Bethel, M, Cornel, J, Lopes, R, Halvorsen, S, Ambrosio, G, Buse, J, Josse, R, Lachin, J, Pencina, M, Garg, J, Lokhnygina, Y, Holman, R, Peterson, E